TUESDAY, DECEMBER 6, 2016

Valneva


Valneva News

Valenva sees global potential for cholera vaccine

Valenva SE, a pure-play vaccine company, recently released an update about the DUKORAL vaccine that it acquired from Crucell Holland BV. Read More »

Valneva unveils two recent EB66 agreements

Valneva recently announced that it has signed two new EB66 agreements with Kaketsuken, which is a Japanese pharmaceutical company, and Fatro, an Italian firm. Read More »

Valneva begins Phase II Clostridium difficile vaccine trial

Valneva SE, a biotechnology company based in Europe, recently started Phase II clinical trial of its VLA84-201 prophylactic vaccine treatment for Clostridium difficile, a bacteria that is notoriously difficult to treat. Read More »

Valneva's first Phase II trials on TB vaccine show promise

European biotechnology company Valneva SE said recently that its Statens Serum Institut’s (SSI) tuberculosis (TB) vaccine candidate H1/IC31, formulated with Valneva’s proprietary adjuvant IC31, showed positive results in Phase II trials. Read More »